Research and experimental development on biotechnology
Registered Address
6th floor 25 farringdon street, london, EC4A 4AB
Website
-
eleusis therapeutics ltdEstimated Valuation
£771.9k
Pomanda estimates the enterprise value of ELEUSIS THERAPEUTICS LTD at £771.9k based on a Turnover of £673.2k and 1.15x industry multiple (adjusted for size and gross margin).
eleusis therapeutics ltdEstimated Valuation
£0
Pomanda estimates the enterprise value of ELEUSIS THERAPEUTICS LTD at £0 based on an EBITDA of £-873.3k and a 4.57x industry multiple (adjusted for size and gross margin).
eleusis therapeutics ltdEstimated Valuation
£0
Pomanda estimates the enterprise value of ELEUSIS THERAPEUTICS LTD at £0 based on Net Assets of £-9.1m and 1.59x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Eleusis Therapeutics LtdOverview
Eleusis Therapeutics Ltd is a live company located in london, EC4A 4AB with a Companies House number of 10227584. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in June 2016, it's largest shareholder is
eleusis therapeutics holdings ltd
with a 100% stake. Eleusis Therapeutics Ltd is a young,
small sized company, Pomanda has estimated its turnover at
£673.2k with
healthy
growth in recent years.
Pomanda's financial health check has awarded Eleusis Therapeutics Ltd a 1 rating. We use a traffic light system to show it exceeds the industry average on 0 measures and has 6 areas for improvement. Company Health Check FAQs
Health Rating1out of 5
0 Strong
4 Regular
6 Weak
Size
annual sales of £673.2k, make it smaller than the average company (£4.5m)
£673.2k - Eleusis Therapeutics Ltd
£4.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 11%, show it is growing at a similar rate (13.1%)
11% - Eleusis Therapeutics Ltd
13.1% - Industry AVG
Production
with a gross margin of 53.9%, this company has a comparable cost of product (53.9%)
53.9% - Eleusis Therapeutics Ltd
53.9% - Industry AVG
Profitability
an operating margin of -129.7% make it less profitable than the average company (-4.1%)
-129.7% - Eleusis Therapeutics Ltd
-4.1% - Industry AVG
Employees
with 7 employees, this is below the industry average (54)
7 - Eleusis Therapeutics Ltd
54 - Industry AVG
Pay Structure
on an average salary of £83k, the company has an equivalent pay structure (£83k)
£83k - Eleusis Therapeutics Ltd
£83k - Industry AVG
Efficiency
resulting in sales per employee of £96.2k, this is less efficient (£131.4k)
£96.2k - Eleusis Therapeutics Ltd
£131.4k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Eleusis Therapeutics Ltd
- - Industry AVG
Creditor Days
its suppliers are paid after 64 days, this is close to average (60 days)
64 days - Eleusis Therapeutics Ltd
60 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Eleusis Therapeutics Ltd
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 0 weeks, this is less cash available to meet short term requirements (30 weeks)
0 weeks - Eleusis Therapeutics Ltd
30 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 474.4%, this is a higher level of debt than the average (53.1%)
474.4% - Eleusis Therapeutics Ltd
53.1% - Industry AVG
ELEUSIS THERAPEUTICS LTD financials
EXPORT
Eleusis Therapeutics Ltd's latest turnover from December 2023 is estimated at £673.2 thousand and the company has net assets of -£9.1 million. According to their latest financial statements, Eleusis Therapeutics Ltd has 7 employees and maintains cash reserves of £15 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Jun 2017
Turnover
673,223
1,642,375
604,837
494,500
115,941
151,234
Other Income Or Grants
Cost Of Sales
310,597
781,631
297,423
236,815
58,610
74,475
Gross Profit
362,626
860,744
307,414
257,686
57,330
76,758
Admin Expenses
1,235,972
4,442,803
2,600,691
1,589,073
354,173
642,910
202,077
117,157
Operating Profit
-873,346
-3,582,059
-2,293,277
-1,331,387
-296,843
-566,152
-202,077
-117,157
Interest Payable
Interest Receivable
715
2,699
318
79
1,364
2,926
1,156
Pre-Tax Profit
-872,631
-3,579,360
-2,292,959
-1,331,308
-295,479
-563,226
-200,921
-117,157
Tax
Profit After Tax
-872,631
-3,579,360
-2,292,959
-1,331,308
-295,479
-563,226
-200,921
-117,157
Dividends Paid
Retained Profit
-872,631
-3,579,360
-2,292,959
-1,331,308
-295,479
-563,226
-200,921
-117,157
Employee Costs
581,206
312,562
312,487
140,898
68,409
67,699
Number Of Employees
7
4
4
2
1
1
EBITDA*
-873,346
-3,582,059
-2,293,277
-1,331,387
-296,843
-566,152
-202,077
-117,157
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Jun 2017
Tangible Assets
Intangible Assets
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
Stock & work in progress
Trade Debtors
Group Debtors
4,007
27,576
22,330
19,667
Misc Debtors
2,421,255
2,339,777
866,282
53,861
117,304
14,860
3,130
Cash
14,970
12,267
141,988
112,360
46,187
317,653
462,543
misc current assets
total current assets
2,440,232
2,352,044
1,008,270
166,221
191,067
354,843
485,340
total assets
2,440,232
2,352,044
1,008,270
166,221
191,067
354,843
485,340
Bank overdraft
Bank loan
Trade Creditors
55,099
1,669,130
312,607
368,477
30,287
61,574
Group/Directors Accounts
11,470,495
8,929,496
5,282,542
2,016,648
1,141,985
1,012,370
647,372
115,006
other short term finances
hp & lease commitments
other current liabilities
50,521
16,670
97,013
172,029
78,420
45,045
38,888
2,150
total current liabilities
11,576,115
10,615,296
5,692,162
2,557,154
1,250,692
1,118,989
686,260
117,156
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
total liabilities
11,576,115
10,615,296
5,692,162
2,557,154
1,250,692
1,118,989
686,260
117,156
net assets
-9,135,883
-8,263,252
-4,683,892
-2,390,933
-1,059,625
-764,146
-200,920
-117,156
total shareholders funds
-9,135,883
-8,263,252
-4,683,892
-2,390,933
-1,059,625
-764,146
-200,920
-117,156
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Jun 2017
Operating Activities
Operating Profit
-873,346
-3,582,059
-2,293,277
-1,331,387
-296,843
-566,152
-202,077
-117,157
Depreciation
Amortisation
Tax
Stock
Debtors
85,485
1,473,495
812,421
-91,019
107,690
14,393
22,797
Creditors
-1,614,031
1,356,523
-55,870
338,190
-31,287
61,574
Accruals and Deferred Income
33,851
-80,343
-75,016
93,609
33,375
6,157
38,888
2,150
Deferred Taxes & Provisions
Cash flow from operations
-2,539,011
-3,779,374
-3,236,584
-808,569
-402,445
-512,814
-185,986
-115,007
Investing Activities
capital expenditure
Change in Investments
cash flow from investments
Financing Activities
Bank loans
Group/Directors Accounts
2,540,999
3,646,954
3,265,894
874,663
129,615
364,998
647,372
115,006
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
1
1
interest
715
2,699
318
79
1,364
2,926
1,156
cash flow from financing
2,541,714
3,649,653
3,266,212
874,742
130,979
367,924
648,529
115,007
cash and cash equivalents
cash
2,703
-129,721
29,628
66,173
-271,466
-144,890
462,543
overdraft
change in cash
2,703
-129,721
29,628
66,173
-271,466
-144,890
462,543
eleusis therapeutics ltd Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for eleusis therapeutics ltd. Get real-time insights into eleusis therapeutics ltd's credit score, group structure and payment trends.
Perform a competitor analysis for eleusis therapeutics ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in EC4A area or any other competitors across 12 key performance metrics.
eleusis therapeutics ltd Ownership
ELEUSIS THERAPEUTICS LTD group structure
Eleusis Therapeutics Ltd has no subsidiary companies.
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to eleusis therapeutics ltd. Currently there are 1 open charges and 0 have been satisfied in the past.
eleusis therapeutics ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ELEUSIS THERAPEUTICS LTD. This can take several minutes, an email will notify you when this has completed.
eleusis therapeutics ltdCompanies House Filings - See Documents
